

# Cristina Teixeira

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5854121/publications.pdf>

Version: 2024-02-01

113  
papers

2,488  
citations

236925

25  
h-index

206112

48  
g-index

120  
all docs

120  
docs citations

120  
times ranked

4973  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution. <i>Clinical and Translational Oncology</i> , 2022, 24, 319-330.	2.4	3
2	Quality indicators and excellence requirements for a multidisciplinary lung cancer tumor board by the Spanish Lung Cancer Group. <i>Clinical and Translational Oncology</i> , 2022, 24, 446-459.	2.4	9
3	Vaccine Therapy in Non-Small Cell Lung Cancer. <i>Vaccines</i> , 2022, 10, 740.	4.4	4
4	Immunophenotype of tumor-infiltrating lymphocytes in atypical Spitzoid tumors according to the risk of progression. <i>Annals of Diagnostic Pathology</i> , 2022, 60, 151985.	1.3	1
5	Aberrant TIMP-1 overexpression in tumor-associated fibroblasts drives tumor progression through CD63 in lung adenocarcinoma. <i>Matrix Biology</i> , 2022, 111, 207-225.	3.6	9
6	Multiplex RNA-based detection of clinically relevant <i>MET</i> alterations in advanced non-small cell lung cancer. <i>Molecular Oncology</i> , 2021, 15, 350-363.	4.6	17
7	Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform. <i>Clinical Chemistry</i> , 2021, 67, 554-563.	3.2	12
8	P09.15 Severity of Lung Cancer Disease in Hospitalized Patients During COVID-19. <i>Journal of Thoracic Oncology</i> , 2021, 16, S294-S295.	1.1	1
9	P09.28 Access to Intermediate and Intensive Care for Patients With Lung Cancer During the COVID-19 Period. <i>Journal of Thoracic Oncology</i> , 2021, 16, S302-S303.	1.1	0
10	MA03.08 Impact of COVID-19 Pandemic in the Diagnosis and Prognosis of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, S141.	1.1	19
11	EBUS-TBNA Cytological Samples for Comprehensive Molecular Testing in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2084.	3.7	21
12	182P Impact of SARS CoV 2 outbreak in the molecular diagnosis of advanced NSCLC: A retrospective comparative cohort study. <i>Journal of Thoracic Oncology</i> , 2021, 16, S796-S797.	1.1	0
13	Abstract 469: Comprehensive, large scale analysis of ALK, ROS1, RET, NTRK1 and NRG1 transcripts in lung cancer reveals over-expressing, potentially targetable patients. , 2021, , .		0
14	PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain. <i>Diagnostics</i> , 2021, 11, 1452.	2.6	5
15	Molecular Markers and Targets in Melanoma. <i>Cells</i> , 2021, 10, 2320.	4.1	72
16	In Search of the Long-Desired "Copernican Therapeutic Revolution"™ in Small-Cell Lung Cancer. <i>Drugs</i> , 2020, 80, 241-262.	10.9	12
17	TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas. <i>Annals of Translational Medicine</i> , 2020, 8, 1218-1218.	1.7	7
18	Preliminary Report of a Multidisciplinary Task Group for the Study of Immune-Mediated Pulmonary Toxicity. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
19	Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients. <i>Diagnostics</i> , 2020, 10, 902.	2.6	1
20	Using biomarkers to determine optimal combinations with immunotherapy (biomarker discovery) Tj ETQq0 0 0 rgBT JOverlock 10 Tf 50	2.4	3
21	Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. <i>Cancers</i> , 2020, 12, 1124.	3.7	5
22	Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients. , 2020, 1, 101-108.		4
23	Abstract 5594: Immune gene expression by nCounter in mucinous adenocarcinoma lung cancer. , 2020, , .		0
24	Abstract 809: nCounter for detection of clinically relevant alterations in exosomes of non-small cell lung cancer cells and patients. , 2020, , .		0
25	Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2120-2132.	1.1	48
26	AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. <i>Nature Communications</i> , 2019, 10, 1812.	12.8	98
27	Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome. <i>Histopathology</i> , 2019, 75, 799-812.	2.9	29
28	Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC. <i>Oncolmmunology</i> , 2019, 8, 1602460.	4.6	22
29	Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report. <i>Clinical Lung Cancer</i> , 2019, 20, e219-e223.	2.6	15
30	P2.03-17 Optimization of an Ex-Vivo Preclinical Model for Drug Testing. <i>Journal of Thoracic Oncology</i> , 2019, 14, S689.	1.1	0
31	P1.01-56 Increased ROS1 and RET Transcripts in Fusion-Negative NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2019, 14, S380.	1.1	0
32	P2.04-22 Programmed Death 1-mRNA Expression Predicts Benefit to Anti-PD1 Monotherapy in a Prospective Cohort of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, S716-S717.	1.1	0
33	P2.04-61 Preliminary Report of a Multidisciplinary Task Group for the Study of Immune-Mediated Pulmonary Toxicity. <i>Journal of Thoracic Oncology</i> , 2019, 14, S732.	1.1	0
34	EP1.01-41 Feasibility of EBUS-TBNA Cytologies for an Extensive Assessment of Predictive Biomarkers in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, S927-S928.	1.1	1
35	P1.01-43 Programmed-Death Ligand 1 Spectrum in a Large Cohort of Genetically Characterized Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2019, 14, S374.	1.1	0
36	Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	3.0	14

#	ARTICLE	IF	CITATIONS
37	Abstract 131: Concordance of mRNA expression (nCounter) and protein expression (IHC) for the detection of PD-L1 in patients with advanced non-small cell lung cancer (NSCLC). , 2019, , .		0
38	Abstract 4905: Comprehensive characterization of MET alterations in a large cohort of 610 advanced non-small cell lung cancer patients. , 2019, , .		0
39	Abstract 1384: nCounter for detection of clinically relevant alterations in liquid biopsies of solid tumor patients. , 2019, , .		0
40	Abstract 131: Concordance of mRNA expression (nCounter) and protein expression (IHC) for the detection of PD-L1 in patients with advanced non-small cell lung cancer (NSCLC). , 2019, , .		0
41	Abstract 1384: nCounter for detection of clinically relevant alterations in liquid biopsies of solid tumor patients. , 2019, , .		0
42	PD-L1 expression testing in non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876349.	3.2	120
43	RNA Analysis as a Tool to Determine Clinically Relevant Gene Fusions and Splice Variants. Archives of Pathology and Laboratory Medicine, 2018, 142, 474-479.	2.5	16
44	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401774974.	3.2	200
45	P1.09-09 Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients. Journal of Thoracic Oncology, 2018, 13, S553-S554.	1.1	0
46	P3.04-16 A Seven-Gene Expression Signature Reveals Unique Immune-Phenotypes Related to Major Oncogenic-Drivers in NSCLC. Journal of Thoracic Oncology, 2018, 13, S928.	1.1	0
47	P3.04-13 PD-L1-Gene Expression by nCounter Correlates with PD-L1 Protein Expression in Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2018, 13, S927.	1.1	0
48	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget, 2018, 9, 20617-20630.	1.8	36
49	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. Journal of Translational Medicine, 2018, 16, .	4.4	2
50	Response to crizotinib in a non-small-cell lung cancer patient harboring an <i>EML4-ALK</i> fusion with an atypical <i>LTBP1</i> insertion. OncoTargets and Therapy, 2018, Volume 11, 1117-1120.	2.0	4
51	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Annals of Oncology, 2018, 29, 2121-2128.	1.2	74
52	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respiratory Medicine, the, 2018, 6, 771-781.	10.7	167
53	Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform. Translational Cancer Research, 2018, 8, S3-S15.	1.0	3
54	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers.. Journal of Clinical Oncology, 2018, 36, 3076-3076.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Abstract 3924: Aurora B, a potential new target in non-T790M lung cancer cells with acquired resistance to anti-EGFR therapy, is effectively blocked by the MET/AXL/FGFR inhibitor S49076. , 2018, , .		0
56	Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non- Small-Cell Lung Cancer Patients. Clinical Chemistry, 2017, 63, 751-760.	3.2	62
57	Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2017, 26, 713-722.	4.1	17
58	Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. Journal of the National Cancer Institute, 2017, 109, .	6.3	128
59	P3.01-045 Correlation of EGFR Mutation Detection in CtDNA by Two Different Platforms in Advanced NSCLC Patients from a Single Institution. Journal of Thoracic Oncology, 2017, 12, S2218-S2219.	1.1	1
60	P1.01-075 Simultaneous Multiplex Profiling of Gene Fusions, METe14 Mutations and Immune Genes in Advanced NSCLC by NCounter Technology. Journal of Thoracic Oncology, 2017, 12, S1923.	1.1	1
61	P1.07-015 Interferon-Gamma (INFG) as a Biomarker to Guide Immune Checkpoint Blockade (ICB) in Cancer Therapy. Journal of Thoracic Oncology, 2017, 12, S2001.	1.1	0
62	Innate resistance in EGFR mutant non-small cell lung cancer (NSCLC) patients by coactivation of receptor tyrosine kinases (RTKs). Annals of Oncology, 2017, 28, ii1.	1.2	1
63	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nature Communications, 2017, 8, 410.	12.8	117
64	Neutrophils dominate the immune landscape of non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, E468-E469.	1.4	7
65	Interferon-gamma (INFG), an important marker of response to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) and melanoma patients.. Journal of Clinical Oncology, 2017, 35, 11504-11504.	1.6	7
66	New Approaches for Successful Identification of Several Gene Fusion Oncogenes in Paraffin-Embedded Tissue Samples from Advanced Non- Small-Cell Lung Cancer Patients. Journal of Oncology Translational Research, 2017, 03, .	0.2	0
67	Abstract 1739: Analysis of EML4-ALK fusion transcripts in plasma and platelets to monitor response to crizotinib in EML4-ALK positive non-small cell lung cancer patients (NSCLC). , 2017, , .		0
68	Abstract 2723: MET exon 14 skipping mutations in advanced non-small cell lung cancer (NSCLC) are not associated with MET amplification and overexpression. , 2017, , .		0
69	Abstract 3077: Tumor cells with acquired resistance to EGFR inhibitors and overexpression or activation of AXL, MET and FGFR1 are insensitive to single-agent treatment targeting AXL, MET or FGFR. , 2017, , .		0
70	Liquid biopsies: envisioning a future when tissue is avoidable in lung cancer treatment decision-making. Translational Cancer Research, 2017, 6, S1181-S1186.	1.0	0
71	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Oncotarget, 2016, 7, 1066-1075.	1.8	172
72	KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients. Translational Lung Cancer Research, 2016, 5, 511-516.	2.8	20

#	ARTICLE	IF	CITATIONS
73	Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report. <i>Translational Lung Cancer Research</i> , 2016, 5, 532-537.	2.8	5
74	Liquid Biopsy in Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2016, 3, 69.	2.6	48
75	Automated nCounter-based assay for identifying clinically relevant ALK, ROS1 and RET rearrangements in advanced non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2016, 27, vi438.	1.2	0
76	Phlegmasia cerulea dolens and multiple recurrent thrombotic events as the presenting feature of EML4-ALK translocated non-small cell lung cancer. <i>Cancer Treatment Communications</i> , 2016, 6, 4-7.	0.4	0
77	MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 778-788.	5.3	23
78	Abstract 336: S49076, a kinase inhibitor of AXL, MET and FGFR with strong, selective preclinical activity against tumor cells with acquired resistance to EGFR inhibitors not carrying the T790M mutation. , 2016, , .		1
79	Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response. <i>Oncotarget</i> , 2016, 7, 56619-56627.	1.8	16
80	Abstract 265: Cotargeting EGFR, STAT3 and Src-Notch pathways: a promising approach to improve the efficacy of EGFR-TKIs in the treatment of NSCLC patients. , 2016, , .		0
81	Abstract 4344: Comparison of nCounter, immunohistochemistry, RT-PCR and FISH to detect ALK, ROS1 and RET rearrangements in advanced non-small cell lung cancer (NSCLC). , 2016, , .		0
82	BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. <i>Scientific Reports</i> , 2015, 5, 17499.	3.3	55
83	Targeting PD-1/PD-L1 in lung cancer: current perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2015, 6, 55.	2.7	10
84	AXL Mediates Resistance to PI3K $\pm$ Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. <i>Cancer Cell</i> , 2015, 27, 533-546.	16.8	263
85	A Multisite, Randomized Controlled Clinical Trial of Computerized Cognitive Remediation Therapy for Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 41, 1387-1396.	4.3	37
86	EML4-ALK rearrangement in blood platelets and outcome to crizotinib in non-small-cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8082-8082.	1.6	2
87	<i>ROS1</i> rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. <i>Oncotarget</i> , 2015, 6, 10577-10585.	1.8	85
88	Predictive factors for immunotherapy in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 208.	1.7	27
89	Melanoma: oncogenic drivers and the immune system. <i>Annals of Translational Medicine</i> , 2015, 3, 265.	1.7	19
90	Other targeted drugs in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 266.	1.7	9

#	ARTICLE	IF	CITATIONS
91	Assays for predicting and monitoring responses to lung cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2015, 12, 87-95.	3.0	35
92	Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. <i>Cancer Biology and Medicine</i> , 2015, 12, 79-86.	3.0	28
93	Advances in immunotherapy for treatment of lung cancer. <i>Cancer Biology and Medicine</i> , 2015, 12, 209-22.	3.0	50
94	Association of non-disruptive P53 mutations with poor progression-free survival (PFS) in resected breast cancer treated with neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1042-1042.	1.6	0
95	<i>ROS1</i> rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitive impact and genetic variability.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8066-8066.	1.6	0
96	Abstract LB-053: Monitoring rearrangement of EML4-ALK in blood platelets predicts outcome to crizotinib treatment in non-small-cell lung cancer patients. , 2015, , .		0
97	Can we Do Better with Our Current Therapies for Nscl? the Spanish Lung Cancer Group Approach. <i>Annals of Oncology</i> , 2014, 25, iv51.	1.2	0
98	<i>TAZ</i>Is Highly Expressed in Gastric Signet Ring Cell Carcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-6.	1.9	25
99	478 Pharmacological disruption of the Astrocytic Elevated Gene-1 (AEG1) in anticancer intervention: PB0412_3 (PB03) as a first-in-class AEG1 interacting agent. <i>European Journal of Cancer</i> , 2014, 50, 156.	2.8	0
100	514 Hypoxia inducible factor (HIF)-1a expression levels and p53 mutations are prognostic factors for survival in breast cancer patients treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2014, 50, 167.	2.8	0
101	254 Molecular analysis in breast cancer: correlation with Immunohistochemical classification and pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC). <i>European Journal of Cancer</i> , 2014, 50, 85.	2.8	0
102	Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. <i>Translational Lung Cancer Research</i> , 2014, 3, 70-4.	2.8	51
103	ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. <i>Translational Lung Cancer Research</i> , 2014, 3, 122-30.	2.8	25
104	Abstract 4601: Astrocytic elevated gene 1 (AEG1) a target for pharmacological anticancer intervention. , 2014, , .		1
105	ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. <i>International Journal of Cancer</i> , 2013, 133, 235-246.	5.1	16
106	Impact of the new EGF receptor and ALK testing guideline on personalized lung cancer medicine. <i>Personalized Medicine</i> , 2013, 10, 415-417.	1.5	0
107	Epithelial-Mesenchymal Transition Markers and HER3 Expression Are Predictors of Elisidepsin Treatment Response in Breast and Pancreatic Cancer Cell Lines. <i>PLoS ONE</i> , 2013, 8, e53645.	2.5	16
108	ErbB3 expression predicts sensitivity to elisidepsin treatment: in-vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines. <i>International Journal of Oncology</i> , 2012, 41, 317-24.	3.3	16

#	ARTICLE	IF	CITATIONS
109	676 HER3 Expression in Human Breast Carcinomas is Associated With Tumor Size and Estrogen Receptor Status. <i>European Journal of Cancer</i> , 2012, 48, S160.	2.8	0
110	RSK4 inhibition results in bypass of stress-induced and oncogene-induced senescence. <i>Carcinogenesis</i> , 2011, 32, 470-476.	2.8	27
111	Expression of ErbB2 and ErbB3 in resected non-small cell lung cancer (NSCLC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2011, 29, 7037-7037.	1.6	1
112	Central nervous system progression and liquid biopsy in patients with oncogene addicted non-small cell lung cancer treated with ALK/ROS1 inhibitors. <i>Precision Cancer Medicine</i> , 0, 3, 25-25.	1.8	0
113	Targeting molecular alterations in non-small-cell lung cancer: what's next?. <i>Personalized Medicine</i> , 0, , .	1.5	4